Infectious Disease Molecular Diagnostics Outlook 2015

NEW YORK, May 9, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Infectious Disease Molecular Diagnostics Outlook 2015

http://www.reportlinker.com/p0849197/Infectious-Disease-Molecular-Diagnostics-Outlook-2015.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

The molecular diagnostics (MDx) market represents one of the fastest growing segments of global IVD industry. The overall market is estimated to have reached by around US$ 5.4 Billion in 2011 across the globe and is further estimated to grow at a healthy CAGR of around 10% during 2012-2015. Though a very small proportion of government expenditure is imparted for diagnostic care, it influences significant number of medical decisions. There has been a huge increase in the number of technologically advanced molecular diagnostics tests in recent times that led to create a substantial opportunity in the segment. The future landscape will also be impacted by a proliferation in tests volume and active private sector participation.

Infectious diseases account for the leading position in the global MDx market. In 2011, the market contributed around 52% to the revenue patterns attained from the sales of MDx products/technologies. Further dominated by HIV and CT/NG testing, the infectious disease market is anticipated to grow at the CAGR of around 11% during the forecast period, 2012-2015. In this context, our report "Infectious Disease Molecular Diagnostics Outlook 2015", has effectively monitored the current and future outlook of the infectious disease MDx's market as a whole and its segments on an individual basis. Our study has also demonstrated the leading position of key methods used in tests for infectious diseases.

There are some of the prominent players in the infectious molecular diagnostics market who are actively participating in industry development. Companies, such as Roche Molecular Diagnostics, bioMerieux, Becton and Dickinson, Abbott Molecular, and Gen-Probe are the leading market players with high-selling platforms and screening tests used for key infectious diseases. Our report provides an in-depth insight on these players in the competitive landscape section. The section covers an effective insight into the businesses of all the companies and its infectious disease-related diagnostic products.

The report, which is spread in around 90 pages, is a comprehensive analyses, covering all the key aspects of the global infectious disease market. It investigates the current market trends that impact the sector in a significant manner. Moreover, a prudent analysis on the performance of sector in key diseases have been also covered that will be a source of complete knowledge and insight for the investors/clients. Overall, the report is an optimum presentation of infectious disease diagnostics sector worldwide, which caters to all those interested in healthcare/diagnostics domain.

1. Analyst View2. Research Methodology3. Molecular Diagnostics: Current and Emerging Technologies3.1 Nucleic Acid Amplification based Technologies3.1.1 Polymerase Chain Reaction (PCR)3.1.2 Real Time PCR3.1.3 Multiplex PCR3.1.4 Transcription Mediated Amplification (TMA)3.1.5 Nucleic Acid Sequence based Amplification (NASBA)3.1.6 Strand Displacement Amplification (SDA)3.2 Hybridization based Technologies3.2.1 Microarray3.2.2 Fluorescence in Situ Hybridization (FISH)3.3 Sequencing based Technologies4. Industry Trends and Drivers4.1 Expansions and Strategic Activity Fuelling Growth amongst Leading Players4.2 HAI's Diagnostics to Diversify Greatly4.3 Next-Generation Technologies Growing in the Market5. Industry Overview: Current & Future Market Analysis to 20155.1 Molecular Diagnostics Market5.2 Infectious Disease Molecular Diagnostics Market6. Infectious Disease Molecular Diagnostics: Market Segments6.1 HIV6.1.1 Global Disease Burden6.1.2 Market Size: Current and Future Analysis to 20156.1.3 FDA Approved Tests6.1.4 Market Activities6.2 Hepatitis6.2.1 Global Disease Burden (Hepatitis B and C)6.2.2 Market Size: Current and Future Analysis to 20156.2.3 FDA Approved Tests6.2.4 Market Activities6.3 Human Papillomavirus (HPV)6.3.1 Global Disease Burden6.3.2 Market Size: Current and Future Analysis to 20156.3.3 FDA Approved Tests6.3.4 Market Activities6.4 Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (GC)6.4.1 Global Disease Burden6.4.2 Market Size: Current and Future Analysis to 20156.4.3 FDA Approved Tests6.4.4 Market Activities7. Regulatory Framework8. Competitive Landscape8.1 Abbott Laboratories8.2 Becton, Dickinson and Company8.3 Siemens8.4 bioMérieux8.5 Gen-Probe8.6 Cepheid8.7 Qiagen NV8.8 Roche

List of Figures:

Figure 5-1: Molecular Diagnostics Market (Billion US$), 2011-2015Figure 5-2: Molecular Diagnostics Market by Segment (%), 2011Figure 5-3: Molecular Diagnostics Market by Player (%), 2011Figure 5-4: Share of Infectious Diseases in Molecular Diagnostics Market (2011 & 2015)Figure 5-5: Infectious Diseases Molecular Diagnostics Market (Billion US$), 2011-2015Figure 6-1: Infectious Diseases Molecular Diagnostics Market by Disease Segment (%), 2011 & 2015Figure 6-2: New Cases of HIV/AIDS (Million), 2009 & 2010Figure 6-3: Prevalence of HIV/AIDS (Million), 2011 & 2015Figure 6-4: HIV/AIDS Molecular Diagnostics Market (Million US$), 2011-2015Figure 6-5: Prevalence of Hepatitis B (Billion), 2011 & 2015Figure 6-6: HBV Molecular Diagnostics Market (Million US$), 2011-2015Figure 6-7: HCV Molecular Diagnostics Market (Million US$), 2011-2015Figure 6-8: Number of New Cervical Cancer Cases (Million), 2011 & 2015Figure 6-9: HPV Molecular Diagnostics Market (Million US$), 2011-2015Figure 6-10: CT/GC Molecular Diagnostics Market (Million US$), 2011-2015Figure 7-1: US - Approved Molecular Diagnostic Products by Segment (%)

List of Tables:

Table 3-1: Key PCR based Tests for Infectious DiseasesTable 3-2: Key Real Time PCR based Tests for Infectious DiseasesTable 3-3: Key Multiplex PCR based Tests for Infectious DiseasesTable 3-4: Key TMA based Tests for Infectious DiseasesTable 3-5: Key NASBA based Tests for Infectious DiseasesTable 3-6: Key SDA based Tests for Infectious DiseasesTable 3-7: Key Probe based Tests for Infectious DiseasesTable 3-8: Key Microarray based Tests for Infectious DiseasesTable 3-9: Key Sequencing based Tests for Infectious DiseasesTable 6-1: Prevalence of HIV/AIDS by Region (2010)Table 6-2: FDA Approved HIV Molecular Diagnostics TestsTable 6-3: Prevalence of Chronic Hepatitis B by RegionTable 6-4: FDA Approved Hepatitis Molecular Diagnostics TestsTable 6-5: Contribution of HPV in Cancer by TypeTable 6-6: HPV Prevalence by TypeTable 6-7: HPV Prevalence by RegionTable 6-8: FDA Approved HPV Molecular Diagnostics TestsTable 6-9: Estimated New Cases of Chlamydia in Adults (Million)Table 6-10: Estimated New Cases of Gonorrhea in Adults (Million)Table 6-11: FDA Approved CT/GC Molecular Diagnostics TestsTable 8-1: Abbott Molecular - Infectious Disease Molecular Diagnostic ProductsTable 8-2: BD Diagnostics - Infectious Disease Molecular Diagnostic ProductsTable 8-3: Siemens Healthcare - Infectious Disease Diagnostic ProductsTable 8-4: bioMerieux - Infectious Disease Molecular Diagnostic ProductsTable 8-5: Gen-Probe - Key Infectious Disease Diagnostic ProductsTable 8-6: Cepheid - Infectious Disease Diagnostic ProductsTable 8-7: Qiagen N.V. - Infectious Disease Diagnostic ProductsTable 8-8: Roche Molecular Diagnostics - Infectious Disease Diagnostics Products

More  

Check our  

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker